Rhythm Pharmaceuticals (RYTM) Q2 2026 earnings review
U.S. Commercial Execution Shines, but European Pricing Bites
Rhythm Pharmaceuticals delivered a breakout quarter driven by the newly approved U.S. launch of IMCIVREE for acquired hypothalamic obesity (HO). U.S. revenue surged 38% sequentially, pushing global revenue to $71.3 million. However, the international picture was less pristine: ex-U.S. revenue fell 13% sequentially due to a $3.8 million retroactive pricing charge in France. On the pipeline front, preliminary Phase 2 data for the next-generation RM-718 injectable showed highly competitive weight-loss numbers, though early patient dropouts require monitoring. In a welcome move for cash burn, management lowered full-year operating expense guidance.
🐂 Bull Case
The U.S. commercial launch for acquired HO is gaining rapid traction. Start forms jumped to over 400 (up from >150 reported in the first six weeks), translating to a massive 38% sequential bump in U.S. sales.
Phase 2 data for the once-weekly RM-718 matched or beat legacy therapies (-11.6% BMI at 16 weeks), proving Rhythm has a viable next-generation franchise defense that minimizes hyperpigmentation.
🐻 Bear Case
A $3.8 million retroactive 'Contribution M' charge in France derailed international growth. This exposes the underlying lumpiness and reimbursement risks associated with European orphan drug launches.
SG&A expenses jumped 46% YoY to $67.4 million. Rhythm must prove that the aggressive scaling of its commercial footprint will yield sustained, profitable growth rather than just an initial launch bolus.
⚖️ Verdict: 🟢
Bullish. The core thesis—that acquired HO is a transformative commercial opportunity—is playing out flawlessly in the U.S. While the European pricing charge is frustrating, it is a one-time true-up that obscures otherwise solid global patient demand.
Key Themes
U.S. HO Launch: Explosive Initial Demand
The U.S. launch is undeniably accelerating. In Q1, management reported >150 start forms in the first six weeks. By the end of Q2, that number eclipsed 400 from roughly 300 prescribers. This drove a $14.1 million sequential jump in U.S. revenue (to $51.0 million). The breadth of the prescriber base indicates broad awareness beyond just specialized academic centers.
RM-718 Data Validates the Next-Gen Pipeline
Preliminary Phase 2 data for the once-weekly MC4R agonist RM-718 showed an 11.6% mean BMI reduction at 16 weeks. This compares highly favorably to historical data for both setmelanotide (-10.1% at 16 weeks) and the oral bivamelagon (-10.1% at 14 weeks). Crucially, there were only two mild, localized cases of hyperpigmentation—a major quality-of-life improvement over setmelanotide.
International Stumbles on European Regulations
A key contradiction to the 'seamless global rollout' narrative emerged this quarter. Ex-U.S. revenue actually reversed, falling 13% sequentially from $23.2M to $20.3M. This was driven by a $3.8 million retroactive charge associated with the 'Contribution M' mechanism in France ($3.1M applied to prior periods). This highlights the complex, punitive regulatory pricing environments in the EU that can capsize international revenue models unpredictably.
Shifting Expense Mix: The Cost of Commercialization
Rhythm is firmly transitioning from an R&D engine to a commercial machine, and the income statement proves it. SG&A expenses are accelerating, up 46% YoY to $67.4 million. While necessary to support the 42-person U.S. sales force and the 50-person Japanese buildout, operating losses remain stubbornly anchored around the $50 million mark.
RM-718 Early Dropout Rate Requires Monitoring
While RM-718's efficacy is strong, the safety profile holds a red flag. Of the 11 patients enrolled, two discontinued treatment due to adverse events (injection site induration and nausea). An 18% AE-driven dropout rate in a very small open-label trial is elevated and warrants close monitoring as the trial progresses to larger cohorts.
Lowered Operating Expense Guidance Preserves Cash
In a surprise positive for capital preservation, management lowered its FY26 Non-GAAP Operating Expense guidance to $363M-$397M. This is a significant cut from the $385M-$415M range provided in Q1. Combined with $330.9 million in cash, this cements the company's claim of having at least 24 months of runway.
Other KPIs
Stable YoY compared to the $(48.0) million loss in 25Q2. The massive surge in U.S. product revenue was almost entirely consumed by the parallel acceleration in SG&A expenses required to execute the HO launch.
Declined from $388.9 million at the end of 2025. The company is burning roughly $30-$40 million per quarter, but the recent lowering of FY26 OpEx guidance provides a stronger buffer to reach cash-flow breakeven without near-term dilution.
Guidance
Decelerating. Management tightened and lowered the range from the previously guided $385 - $415 million. The new midpoint ($380M) implies tighter cost controls over both R&D ($175M-$195M) and SG&A ($188M-$202M) than previously telegraphed.
Key Questions
European Run-Rate Transparency
Excluding the $3.8 million French Contribution M charge, ex-U.S. revenue would have been roughly $24.1 million. Is this the normalized baseline we should use for Q3, or are there other looming European pricing true-ups expected?
RM-718 Discontinuation Dynamics
An 18% discontinuation rate due to adverse events (2 out of 11) in the RM-718 Phase 2 trial is notable. Is this purely an artifact of small sample size, or are there specific mitigation strategies being applied to the injection site induration?
Drivers of Guidance Reduction
You lowered the midpoint of FY26 Non-GAAP Operating Expenses by $20 million. Was this driven by realized efficiencies in the commercial rollout, or simply a delay in pipeline trial spend (e.g., the bivamelagon Phase 3)?